Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.[2]
Clinical data | |
---|---|
Trade names | Ontak, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611024 |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 70-80 min |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C2560H4042N678O799S17 |
Molar mass | 57647.46 g·mol−1 |
![]() ![]() |
Medical uses
editDenileukin is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Adverse effects
editThe prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.
Society and culture
editLegal status
editIn 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.[3]
References
edit- ^ "Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999". DailyMed. Retrieved 9 August 2024.
- ^ Turturro F (January 2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Review of Anticancer Therapy. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. S2CID 9028829.
- ^ Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 (11): 1445–51. doi:10.1517/14712590903348135. PMID 19817678. S2CID 23956460.